Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | APLNR | P35414 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | CTSH | P09668 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 3/20 | 0.47 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608138 | 0.91 | APLNR (0.49) | KDM1AAPLNRC5AR1 | |
| SCHEMBL29606988 | 0.89 | C5AR1 (0.51) | KDM1AAPLNRMAOBKDM5AKDM1B | |
| SCHEMBL31696335 | 0.85 | KDM1A (0.54) | KDM1AMAOBKDM5AKDM1B | |
| SCHEMBL29607547 | 0.84 | REN (0.53) | KDM1AAPLNRMAOBKDM5AKDM1B | |
| SCHEMBL29551839 | 0.84 | APLNR (0.55) | MC4RAPLNRCTSLCTSSCTSK | |
| SCHEMBL31256950 | 0.83 | CTSL (0.51) | MC4RAPLNRCTSLCTSSCTSK | |
| SCHEMBL29607931 | 0.82 | C5AR1 (0.55) | MC4RAPLNRCTSLCTSSCTSK | |
| SCHEMBL29607221 | 0.82 | C5AR1 (0.53) | MC4RAPLNRCTSLCTSSCTSK | |
| SCHEMBL3215690 | 0.82 | MAPK8 (0.51) | KDM1AMAOBKDM5AKDM1B | |
| SCHEMBL30844390 | 0.82 | MAPK8 (0.54) | KDM1AMAOBKDM5AKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | KDM1A 2481/4885MC4R 101/4885APLNR 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.